SCHEMBL24893262

SCHEMBL24893262

Cc1ccc(I)c(-c2ccnn2C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
MAPT P10636 2/20 0.43
COMT P21964 1/20 0.40
SCN9A Q15858 3/20 0.36
CYP1A2 P05177 2/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
METAP2 P50579 1/20 0.36
DRD1 P21728 1/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
BRD4 O60885 2/20 0.36
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
LMNA P02545 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HTR2A P28223 2/20 0.34
HTR2C P28335 2/20 0.34
ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16020175 0.82 ESRRA (0.48) ALDH1A1MAPTCOMTSCN9ACYP1A2
SCHEMBL13144356 0.79 MAPT (0.50) ALDH1A1MAPTCOMTSCN9AKDM4E
SCHEMBL13036097 0.79 ALDH1A1 (0.46) ALDH1A1MAPTCOMTSCN9ACYP1A2
SCHEMBL16301302 0.79 DRD1 (0.49) ALDH1A1MAPTCOMTSCN9ACYP1A2
SCHEMBL16900307 0.77 ALDH1A1 (0.41) ALDH1A1MAPTCOMTSCN9ACYP1A2
SCHEMBL15248968 0.77 HTR2A (0.53) ALDH1A1MAPTSCN9ABRD4KDM4E
SCHEMBL9911401 0.76 ALDH1A1 (0.54) ALDH1A1MAPTCOMTCYP11B1CYP11B2
SCHEMBL16277376 0.71 CSNK2A1 (0.45) ALDH1A1MAPTPDE3BPDE3AKDM4E
SCHEMBL24182169 0.71 SCN9A (0.45) ALDH1A1MAPTCOMTSCN9ACYP1A2
SCHEMBL3447723 0.70 CYP1A2 (0.54) ALDH1A1COMTCYP1A2DRD1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4119141-A1 NELOTANSERIN FOR THE PROPHYLAXIS AND TREATMENT OF REM SLEEP BEHAVIOR DISORDER Axovant Sciences GmbH (CH) 2023-01-18 EP disclosed